The [Chinese] state mobilizes the financial resources and the research capacities not just from pharmaceutical firms but also universities, research institutes, high biosafety level labs and high tech firms.
In some cases though, the state is not helping but rather hindering the process. A recent example of that is CanSino’s agreement with Canada to have clinical trials. The candidate vaccine was stuck at China Customs for more than six weeks. Eventually CanSino had to give up, as the government was showing no sign that it would green light the partnership.
Many government actors in China thus intervene in the process of vaccine development and distribution. This also includes the Ministry of Foreign Affairs, which has been making pledges to countries in sub-Saharan Africa, Latin America and Southeast Asia to prioritize the vaccine access to these countries.